Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2018-07
-
The purpose of the present
2023-06-15

The purpose of the present study is (1) to characterize AChE from the monogonont B. koreanus and to analyze the modulation of the AChE activity and its transcription level after exposure to six pharmaceuticals, (2) to evaluate the usefulness of AChE as a molecular biomarker upon pharmaceutical expos
-
br Discussion Arginase and Arginase are homologous enzymes t
2023-06-09

Discussion Arginase 1 and Arginase 2 are homologous enzymes that consume l-arginine to produce l-ornithine and urea [14], [15]. These enzymes compete with NO synthases for the same substrate [14], [15], [30], and therefore may reduce NO production [21], [24], [30]. The colocalization of arginases
-
br Conclusions In summary aromatase mRNA expression in
2023-06-09

Conclusions In summary, aromatase mRNA expression in the dacomitinib mg of A. leptorhynchus shows a similar distribution pattern as seen in other teleosts with expression detected in the forebrain and the pituitary gland. The lack of aromatase mRNA expression in the midbrain and hindbrain of A.
-
br The prevalence of diabetes
2023-06-06

The prevalence of diabetes is increasing globally, and the situation is particularly alarming in Asia. The prevalence of diabetes in China has increased dramatically, from around 1% in 1980 to the most recent estimate of 9.7% according to a nationwide survey . Cumulative evidence shows that type 2
-
RNA interference assays have shown that the
2023-06-06

RNA interference assays have shown that the inhibition of AMPK expression leads to increases in TNF-α, IL-6 and cyclooxygenase-2 (COX-2) levels after LPS stimulus, whereas the transfection of macrophages with a constitutively active form of AMPKα1 results in decreased LPS-induced TNF-α and IL-6 prod
-
br Acknowledgments br Introduction Within the classical secr
2023-06-02

Acknowledgments Introduction Within the classical secretory pathway, transmembrane and soluble cargos travel via the endoplasmic reticulum (ER) and Golgi apparatus en route to their final destinations [1]. However, at a post-Golgi level, trafficking routes can diverge. In this context, the tra
-
YC 1 Inhibitors of mPGES are considered
2023-05-30

Inhibitors of mPGES-1 are considered as safe alternative to NSAIDs in the treatment of chronic inflammatory diseases that are characterized by excessive PGE2 production (Bahia et al., 2014; Khurana and Jachak, 2016; Koeberle et al., 2016; Korotkova and Jakobsson, 2014; Norberg et al., 2013; Psarra e
-
A variety of quinazoline or fused pyrimidine
2023-05-30

A variety of quinazoline or fused pyrimidine-substituted diaminotriazoles showed sub-100nM inhibition of Axl (). Diaminotriazoles similarly substituted with quinolines, isoquinolines and benzothiazoles also showed potent Axl activity (data not shown), but generally exhibited potent cytotoxicity and
-
Disuflo Cy3 azide mg The co crystal structure of blebbistati
2023-05-30

The co-crystal structure of ()-blebbistatin ()- bound to myosin II (PDB: ) was used to scout for possible favorable interactions with the residues lining the binding pocket. Looking at A, we hypothesized that -oriented hydrophilic moieties (e.g. hydroxymethyl) on C of the blebbistatin scaffold might
-
Another factor that is involved in
2023-05-30

Another factor that is involved in the severity of EAE is apoptosis signal-regulating kinase 1 (ASK1), which is one of a growing number of mitogen-activated protein kinase (MAPK) kinase kinases identified in the upstream of the c-Jun N-terminal kinase and p38 MAPK pathways [12]. We previously report
-
nitric oxide synthase inhibitor AP activity is increased by
2023-05-29

AP-1 activity is increased by MAP kinase stimulation in different cell types (Whitmarsh and Davis, 1996), while MKP-1, the enzyme that catalyzes the dephosphorylation and inactivation of MAP kinases in the nucleus, inhibits AP-1 (Rössler et al., 2008, Rössler and Thiel, 2009, Mayer et al., 2011, Thi
-
Applications for protein switches are numerous In
2023-05-29

Applications for protein switches are numerous. In diagnostics, protein switches can detect analytes as components of inexpensive homogeneous assays that do not require specialized equipment or time-consuming incubation and washing steps characteristic of immunoassays [8]. Protein switches have also
-
br Conclusions br Transparency document
2023-05-29

Conclusions Transparency document Acknowledgements This work was supported by a grant from the European Commission FP6 “Neuroprion” – Network of Excellence and Royal Veterinary College Bioveterinary science research project funding. We thank Professor Alun Williams (Cambridge University) fo
-
Based upon these findings the S lipoxygenase seems to
2023-05-29

Based upon these findings, the 12S-lipoxygenase seems to increase membrane excitability by specifically inhibiting M-type K+ channels. The 12S-lipoxygenase is expressed in many parts of mammalian PF-3758309 mg including the cerebrum, cerebellum, hypothalamus, basal ganglia, hippocampus, olfactory b
-
We next developed a system for staging
2023-05-29

We next developed a system for staging severity. Our guiding principles were the following. Two types of information about the research participant are staged independently from each other: (1) grading disease severity using biomarkers and (2) grading the severity of cognitive impairment. Measures u
15585 records 343/1039 page Previous Next First page 上5页 341342343344345 下5页 Last page